Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0000950170-25-058356
Filing Date
2025-04-25
Accepted
2025-04-25 08:32:08
Documents
14

Document Format Files

Seq Description Document Type Size
1 DEFA14A acrv-20250424.htm   iXBRL DEFA14A 16791
2 GRAPHIC img244011982_0.jpg GRAPHIC 39433
3 GRAPHIC img244011982_1.jpg GRAPHIC 1315214
4 GRAPHIC img244011982_2.jpg GRAPHIC 288562
  Complete submission text file 0000950170-25-058356.txt   3724363

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT acrv-20250424.xsd EX-101.SCH 7374
16 EXTRACTED XBRL INSTANCE DOCUMENT acrv-20250424_htm.xml XML 1303
Mailing Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472
Business Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472 617-207-8979
Acrivon Therapeutics, Inc. (Filer) CIK: 0001781174 (see all company filings)

EIN.: 825125532 | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-41551 | Film No.: 25870123
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)